在线日韩日本国产亚洲丨少妇伦子伦情品无吗丨欧美性猛交xxxx免费看蜜桃丨精品人妻系列无码一区二区三区丨亚洲精品无码不卡在线播放

Your Good Partner in Biology Research

GPC3 Recombinant Monoclonal Antibody

  • 中文名稱:
    GPC3重組抗體
  • 貨號:
    CSB-RA009705MA1HU
  • 規格:
    ¥1320
  • 圖片:
    • Overlay Peak curve showing THP-1 cells surface stained with CSB-RA009705MA1HU (red line) at 1:100. Then 10% normal goat serum was Incubated to block non-specific protein-protein interactions followed by the antibody (1μg/1*106cells) for 45 min at 4°C. The secondary antibody used was FITC-conjugated Goat Anti-Mouse IgG(H+L) at 1/200 dilution for 35 min at 4°C. Isotype control antibody (green line) was mouse IgG1 (1μg/1*106cells) used under the same conditions. Acquisition of >10, 010 events was performed.
  • 其他:

產品詳情

  • 產品描述:
    CSB-RA009705MA1HU GPC3重組單克隆抗體是針對Glypican-3(GPC3)靶點開發的高特異性科研工具,該靶點作為細胞膜錨定蛋白通過調控Wnt、Hedgehog等信號通路參與胚胎發育及腫瘤發生。研究表明,GPC3在肝細胞癌、肝母細胞瘤及惡性黑色素瘤中呈現顯著高表達特征,其表達水平與腫瘤進展及預后密切相關,是當前腫瘤生物學研究的熱點分子。本產品經ELISA和流式細胞技術(FC)雙重驗證,在推薦稀釋度(FC 1:20-1:500)范圍內展現出優異的抗原結合能力與批次穩定性,可精準識別天然構象及重組GPC3蛋白。適用于體外腫瘤細胞表面標志物檢測、腫瘤微環境解析、靶向藥物作用機制研究等科研場景,為肝癌等實體腫瘤的分子分型、治療靶點驗證以及抗體藥物開發提供可靠檢測方案,廣泛應用于細胞模型構建、功能實驗驗證及高通量篩選平臺建設等基礎研究領域。
  • Uniprot No.:
  • 基因名:
  • 別名:
    DGSX antibody; Glypican proteoglycan 3 antibody; Glypican-3 [Precursor] antibody; Gpc3 antibody; GPC3_HUMAN antibody; GTR2 2 antibody; GTR2-2 antibody; Heparan sulphate proteoglycan antibody; Intestinal protein OCI 5 antibody; Intestinal protein OCI-5 antibody; MXR7 antibody; OCI 5 antibody; OCI-5 antibody; OCI5 antibody; SDYS antibody; Secreted glypican-3 antibody; SGB antibody; SGBS antibody; SGBS1 antibody
  • 反應種屬:
    Human
  • 免疫原:
    Recombinant Human GPC3 protein
  • 免疫原種屬:
    Homo sapiens (Human)
  • 標記方式:
    Non-conjugated
  • 克隆類型:
    Monoclonal
  • 抗體亞型:
    Mouse IgG
  • 純化方式:
    Affinity-chromatography
  • 克隆號:
    8D11
  • 濃度:
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液:
    Preservative: 0.03% Proclin 300
    Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
  • 產品提供形式:
    Liquid
  • 應用范圍:
    ELISA, FC
  • 推薦稀釋比:
    Application Recommended Dilution
    FC 1:20-1:500
  • Protocols:
  • 儲存條件:
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期:
    Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
  • 用途:
    For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

  • 功能:
    Cell surface proteoglycan that bears heparan sulfate. Negatively regulates the hedgehog signaling pathway when attached via the GPI-anchor to the cell surface by competing with the hedgehog receptor PTC1 for binding to hedgehog proteins. Binding to the hedgehog protein SHH triggers internalization of the complex by endocytosis and its subsequent lysosomal degradation. Positively regulates the canonical Wnt signaling pathway by binding to the Wnt receptor Frizzled and stimulating the binding of the Frizzled receptor to Wnt ligands. Positively regulates the non-canonical Wnt signaling pathway. Binds to CD81 which decreases the availability of free CD81 for binding to the transcriptional repressor HHEX, resulting in nuclear translocation of HHEX and transcriptional repression. Inhibits the dipeptidyl peptidase activity of DPP4. Plays a role in limb patterning and skeletal development by controlling the cellular response to BMP4. Modulates the effects of growth factors BMP2, BMP7 and FGF7 on renal branching morphogenesis. Required for coronary vascular development. Plays a role in regulating cell movements during gastrulation.
  • 基因功能參考文獻:
    1. The areas under the receiver operating curve (AUROC) value, sensitivity and specificity of glypican 3 (GPC3) for hepatoblastoma (HB) pretreatment group versus all controls were all significantly lower than those of alpha-fetoprotein (AFP). PMID: 28378832
    2. GPC3 is operating through an intricate molecular signaling network. From the balance of these interactions, the inhibition of breast metastatic spread induced by GPC3 emerges. PMID: 30267212
    3. Its surface is modified with anti-GPC3 antibody. PMID: 29916268
    4. data suggest that transcriptionally targeted delivery of transgene in HCC cells can be achieved using the GPC3 promoter and this targeting strategy produces limited toxicity to normal liver cells PMID: 29563582
    5. High GPC3 expression is associated with Hepatocellular Carcinoma. PMID: 28429175
    6. Study demonstrated that GPC3 expression is inversely associated with glucose metabolism, suggesting that GPC3 may play a role in regulating glucose metabolism in hepatocellular carcinoma. PMID: 29398870
    7. the intravenous injection of SF-PL/siGPC3 into nude mice bearing subcutaneous human HepG2 xenografts effectively inhibited tumor growth and also increased the survival rates of animals. These results revealed the great potential of the PEI-modified liposomal nanomedicine carrying SF and siGPC3 to improve Hepatocellular carcinomatreatment PMID: 29106433
    8. Invasive hepatocellular carcinoma (HCC) samples and HCC cell lines with high metastatic potential exhibited higher MXR7 expression. Overexpression of MXR7 promoted epithelial-mesenchymal transition (EMT) progress, and MXR7 depletion repressed the EMT phenotype. Human MXR7 protein is a mediator of EMT and metastasis in HCC. PMID: 28812296
    9. Overexpression of GPC3 was significantly associated with poor prognosis in patients with hepatocellular carcinoma. PMID: 29901640
    10. These data show that glycanation and convertase maturation are not required for soluble mutant GPC3 to inhibit hepatocellular carcinoma cell proliferation. PMID: 29345911
    11. Data indicate that several microRNAs targeting the oncogenic functions of glypican-3 (GPC3). PMID: 28476031
    12. presence distinguishes aggressive from non-aggressive odontogenic tumors PMID: 27647326
    13. GPC3 as a potential metastasis suppressor gene and suggest its value as a prognostic marker in gastric cancer. PMID: 27259271
    14. In this study we systematically evaluated a series of CAR constructs targeting glypican-3 (GPC3), which is selectively expressed on several solid tumors. We compared GPC3-specific CARs that encoded CD3zeta (Gz) alone or with costimulatory domains derived from CD28 (G28z), 4-1BB (GBBz), or CD28 and 4-1BB (G28BBz). PMID: 27530312
    15. Data indicate that glypican-3 (GPC3) is an important regulator of epithelial-mesenchymal transition (EMT) in breast cancer, and a potential target for procedures against breast cancer metastasis. PMID: 27507057
    16. Glypican-3 overexpression in Wilms tumor correlates with poor overall survival. PMID: 28432433
    17. glypican-3 has a role in HBV-related hepatocellular carcinoma PMID: 27286460
    18. MOSPD1 is a possible candidate gene for DORV, probably in combination with GPC3. Further studies of the combined functions of MOSPD1 and GPC3 are needed, and identification of additional patients with MOSPD1 and GPC3 duplication should be pursued PMID: 28636109
    19. Glypican-3 is correlated with the clinical malignant behavior of hepatocellular carcinoma and its phenotype changes from positive to negative during tumor cells differentia- tion. PMID: 28087980
    20. The diagnostic sensitivity for hepatocellular carcinoma increased to 72.8% (206 of the 283) when glypican 3 was combined with alpha-fetoprotein. PMID: 26370140
    21. The lncRNA glypican 3 antisense transcript 1 (GPC3-AS1) has been reported to be a potential biomarker for hepatocellular carcinoma (HCC) screening. We observed a significant upregulation of GPC3-AS1 in HCC. Increased expression of GPC3-AS1 was associated with alpha-fetoprotein, tumor size, microvascular invasion, encapsulation, Barcelona Clinic Liver Cancer stage, and worse prognosis of HCC patients. PMID: 27573079
    22. study provides the first evidence that GPC3 can modulate the PCSK9 extracellular activity as a competitive binding partner to the LDLR in HepG2 cells. PMID: 27758865
    23. By subsequent Sanger sequencing of genomic DNA we could map the chromosomal break points to define a deletion size of 43,617 bp including exons 5 and 6 of the GPC3 gene. PMID: 28371070
    24. This is the first study in which the optimal HLA-A*0201 GPC3 epitopes were screened from a large number of candidates predicted by three software. The optimized HLA-A*0201 GPC3 peptides will provide new epitope candidates for hepatocellular carcinoma (HCC) immunotherapy. PMID: 27102087
    25. GPC3 and KRT19 overexpression are associated with carcinogenesis, progression, and poor prognosis in patients with PDAC and a valuable biomarker for diagnosis of PDAC. PMID: 27689616
    26. The clinical implication of GPC3 detection and targeting in the management of patients with hepatocellular carcinoma. Review. PMID: 26755876
    27. Glypican 3 expression showed a significant difference between endometrioid endometrial carcinoma and serous endometrial carcinoma, and it was significantly correlated with tumor grade, stage and myometrial invasion PMID: 26722522
    28. Data show that notum and glypican-1 and glypican-3 gene expression during colorectal cancer (CRC) development and present evidence to suggest them as potential new biomarkers of CRC pathogenesis. PMID: 26517809
    29. GPC3 expression was measured in hepatocellular carcinoma at different stages and correlated with prognosis. CK19+/GPC3+ HCC has the highest risk of intrahepatic metastasis, microvascular invasion, regional lymph node involvement, and distant metastasis. PMID: 26977595
    30. Review: Glypican-3 is a highly specific biomarker for the diagnosis of hepatocellular carcinoma and a promising therapeutic target. PMID: 26256079
    31. In South Korean hepatocellular carcinoma patients, GPC3 expression was more frequent in hepatocellular carcinoma with aggressive features, but it was not an independent prognostic biomarker. PMID: 26764243
    32. In this meta-analysis, GPC3 was found to be acceptable as a serum marker for the diagnosis of hepatocellular carcinoma. PMID: 26502856
    33. GPC3 may be a candidate marker for detecting lung squamous cell carcinoma. PMID: 26345955
    34. study suggests that GPC3 is involved in HCC cell migration and motility through HS chain-mediated cooperation with the HGF/Met pathway, showing how HS targeting has potential therapeutic implications for liver cancer PMID: 26332121
    35. potential role of GPC3 in urothelial carcinogenesis warrants further investigation, especially the potential use of Glypican-3 for therapeutic and diagnostic purposes PMID: 25896897
    36. Downregulation of glypican-3 expression increases migration, invasion, and tumorigenicity of ovarian cancer. PMID: 25967456
    37. GPC3 expression is an independent prognostic factor for postoperative hepatocellular carcinoma PMID: 25432695
    38. Identify a GPC3-specific T-cell receptor. Expression of this receptor by T cells allows them to recognize and kill GPC3-positive hepatoma cells. PMID: 26052074
    39. High expression of glypican-3 is associated hepatoblastoma. PMID: 25735325
    40. GPC3 and E-cadherin expressions are not independent prognostic factors in CRC. PMID: 25619476
    41. In HCC patients, sGPC3N levels were significantly increased (mean/median, 405.16/236.19 pg mL(-1) ) compared to healthy controls (p < 0.0001), and 60% of HCC cases (69/115) showed sGPC3N levels that were higher than the upper normal limit. PMID: 25784484
    42. GPC3 contributes to hepatocellular carcinoma progression and metastasis through impacting epithelial-mesenchymal transition of cancer cells, and the effects of GPC3 are associated with ERK activation. PMID: 25572615
    43. Most cases of hepatoblastoma and yolk sac tumor, and some cases of other tumors were found to express GPC3. On the other hand, GPC3 was physiologically expressed during the fetal and neoinfantile period under 1 year of age. PMID: 25344940
    44. OPN, SPINK1, GPC3 and KNPA2 were significantly over-expressed in HCC tissues. These genes may be useful in developing future biomarkers and therapeutic strategies for HCC PMID: 25862856
    45. Data indicate that zinc-fingers and homeoboxes 2 (ZHX2) suppresses glypican 3 (GPC3) transcription by binding with its core promoter. PMID: 25195714
    46. propose that the structural changes generated by the lack of cleavage determine a change in the sulfation of the HS chains and that these hypersulfated chains mediate the interaction of the mutant GPC3 with Ptc PMID: 25653284
    47. GPC3 is associated with the HCC cell biological behavior. PMID: 25270552
    48. Data indicate that the triple stain of reticulin, glypican-3, and glutamine synthetae is useful in the differentiation of hepatocellular carcinoma, hepatic adenoma, and focal nodular hyperplasia. PMID: 25822763
    49. Data shows that GPC3 gene expression is downregulated in primary clear cell renal cell carcinoma; its overexpression arrest cells in G1 phase suggesting its role as tumor suppressor in clear cell renal cell carcinoma. PMID: 25168166
    50. This study demonstrated that highly expression of GPC3 could enrich hepatocellular carcinoma -related genes' mRNA expression and positive associate with dysplasia in cirrhotic livers. PMID: 25542894

    顯示更多

    收起更多

  • 相關疾?。?/div>
    Simpson-Golabi-Behmel syndrome 1 (SGBS1)
  • 亞細胞定位:
    Cell membrane; Lipid-anchor, GPI-anchor; Extracellular side.
  • 蛋白家族:
    Glypican family
  • 組織特異性:
    Highly expressed in lung, liver and kidney.
  • 數據庫鏈接:

    HGNC: 4451

    OMIM: 300037

    KEGG: hsa:2719

    STRING: 9606.ENSP00000377836

    UniGene: Hs.644108



主站蜘蛛池模板: 色狠狠成人综合网| 玩弄丰满少妇人妻视频| 国内精品国语自产拍在线观看 | 中国少妇videos呻吟| 国产内射爽爽大片| 无码少妇一区二区| 国产男女无遮挡猛进猛出| 98久久人妻少妇激情啪啪| 伊人久久大香线蕉综合影院首页| 国产精品无码一本二本三本色| 艳妇乳肉豪妇荡乳| 三级久久试看3分钟| 中文字幕精品av一区二区五区 | 亚洲欧美综合在线天堂| 中文字幕无码一区二区免费| 三上悠亚的av片在线无码| 两个男人吮她的花蒂和奶水视频| 久久亚洲精品无码va白人极品| 欧美大屁股xxxxhd黑色| 亚洲伊人成综合人影院青青青| 国产又色又爽又黄的在线观看| 欧美黑人又粗又大又爽免费| 香蕉人妻av久久久久天天| 日韩高清成片免费视频| 亚洲无线卡一卡二| 麻豆av一区二区天美传媒 | 人妻人人做人做人人爱| 看成年全黄大色黄大片| 亚洲区激情区无码区日韩区| 亚洲精品国产suv| 一本久久a久久精品综合| av色国产色拍| 又黄又爽的60分钟视频| 午夜精品国产精品大乳美女| 国产免费mv大全视频网站| 久久久久久亚洲综合影院| 东京热久久综合久久88| 久久人人爽人人爽人人片| 婷婷五月俺也去人妻| 精品一品国产午夜福利视频| 国产熟女一区二区三区四区五区|